Biosyngen receives US FDA Nod to begin phase lI trial of Cell therapy

Biosyngen, a company focused on immuno-oncology, stated that its EBV-specific CAR-T cell therapy, BRG01, has received approval from the US Food and Drug Administration (FDA) to advance into a crucial phase II clinical trial. This is the initial...